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Introduction
Three different small ubiquitin-related modifier (SUMO) pro-
teins, SUMO1 and the twins SUMO2/3, can be conjugated to 
their target proteins in an enzymatic pathway that resembles 
ubiquitination.  This  posttranslational  modification  of  pro-
teins with SUMO (sumoylation) is involved in a variety of 
different cellular pathways, often by regulating protein–protein 
or  protein–DNA  interactions  (Johnson,  2004;  Hay,  2005;   
Geiss-Friedlander and Melchior, 2007; Wilkinson and Henley, 
2010). More recently, increasing evidence suggests that SUMO 
may also contribute to protein solubility (Palacios et al., 2005; 
Fei et al., 2006; Mukherjee et al., 2009; Janer et al., 2010).
A common feature of sporadic forms of neurodegenerative 
disease is a decreased solubility of specific disease-associated 
proteins and, concomitantly, an enhanced pathological propen-
sity to form aggregates. The identification of point mutations, 
deletions,  or  trinucleotide  extensions  in  aggregating  proteins 
causing hereditary forms of neurodegenerative diseases further 
P
osttranslational modification of proteins by attach-
ment  of  small  ubiquitin-related  modifier  (SUMO) 
contributes to numerous cellular phenomena. Su-
moylation sometimes creates and abolishes binding inter-
faces, but increasing evidence points to another role for 
sumoylation in promoting the solubility of aggregation-
prone proteins. Using purified -synuclein, an aggrega-
tion-prone protein implicated in Parkinson’s disease that 
was previously reported to be sumoylated upon over-
expression, we compared the aggregation kinetics of un-
modified and modified -synuclein. Whereas unmodified 
-synuclein formed fibrils, modified -synuclein remained 
soluble. The presence of as little as 10% sumoylated   
-synuclein was sufficient to delay aggregation significantly 
in vitro. We mapped SUMO acceptor sites in -synuclein 
and showed that simultaneous mutation of lysines 96 and 
102  to  arginine  significantly  impaired  -synuclein  su-
moylation in vitro and in cells. Importantly, this double 
mutant showed increased propensity for aggregation and 
cytotoxicity in a cell-based assay and increased cytotox-
icity in dopaminergic neurons of the substantia nigra   
in vivo. These findings strongly support the model that   
sumoylation promotes protein solubility and suggest that 
defects in sumoylation may contribute to aggregation-
induced diseases.
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-Synuclein is sumoylated in vitro and  
in cell lines
We first tested whether -synuclein can be conjugated in a cell-
free system. To this purpose, recombinant -synuclein was in-
cubated with SUMO2, the E1-activating enzyme Aos1/Uba2, 
the E2-conjugating enzyme (Ubc9), and the E3 ligase PIASx 
or catalytic fragments of the E3 ligase RanBP2 (BP2FG 
and Ir1+M). As shown in Fig. 1 A (myc–-synuclein staining),   
-synuclein could be efficiently sumoylated in the presence of 
an E3 ligase (see Fig. S1 B for additional SUMO1 staining). 
Next, we confirmed -synuclein as a target for SUMO con-
jugation  in  HEK293T  cells  (Fig.  1  B).  Plasmids  encoding 
His6-tagged  SUMO2  and  -synuclein  were  cotransfected  in 
HEK293T cells. His6-SUMO2 substrates were isolated by Ni
2+ 
affinity chromatography. Only in the presence of His6-SUMO2 
and -synuclein could higher molecular mass species (35 kD) 
immunopositive for -synuclein be detected, demonstrating a 
covalent SUMO conjugation to -synuclein.
-Synuclein is sumoylated in the brain  
of His6-SUMO2 transgenic mice
To provide proof for -synuclein sumoylation under in vivo cir-
cumstances in the brain, we generated transgenic mice express-
ing His6-SUMO2 under control of the neuron-specific Thy1.2 
promoter (Fig. 1 C). These animals are fertile and have no obvi-
ous abnormalities. Brain lysates from wild-type (WT) and 
His6-SUMO transgenic mice were subjected to Ni
2+ affinity 
chromatography to examine -synuclein sumoylation.
In these His6-SUMO2 transgenic mice, we observed an 
35-kD -synuclein immunoreactive species, which was simi-
lar to our in vitro and cellular assays, indicating that endogenous 
-synuclein is sumoylated under physiological circumstances 
(Fig. 1 C). The specificity of the His-SUMO2 pull-down, ana-
lyzed by anti-SUMO2 immunoblotting, is shown in Fig. S1 C. 
Our  results  show  that  endogenous  -synuclein  is  efficiently 
conjugated with SUMO2 in the mouse brain and that our trans-
genic mice are suitable tools for in vivo confirmation of neuro-
nal SUMO targets.
Sumoylation of -synuclein abolishes 
amyloid fibril formation in vitro
The central disease-associated propensity of -synuclein to ag-
gregate in vivo can be recapitulated in vitro, as recombinant 
monomeric -synuclein forms amyloid fibrils that are similar to 
-synuclein filaments isolated from patients with synucleinopa-
thies (Crowther et al., 2000; Serpell et al., 2000). Considering 
the high solubility of SUMO, we hypothesized that sumoylation 
may act as a modulator of fibril/aggregate formation, thus main-
taining the aggregation-prone -synuclein in solution. There-
fore, we aimed to characterize the impact of sumoylation on 
-synuclein fibril formation under in vitro conditions. As this 
required several milligrams of purified untagged sumoylated   
-synuclein, we used a system for overproduction of sumoylated 
substrates in Escherichia coli (Uchimura et al., 2004) and puri-
fied  recombinant  sumoylated  -synuclein  from  heat-treated 
bacterial lysates by ion exchange chromatography and gel filtra-
tion. The  aggregation  propensity  of  sumoylated  -synuclein 
supports the causal role of insoluble and aggregated proteins. 
Pathological protein aggregation is thus a prominent feature of 
neurodegenerative diseases like Parkinson’s disease (PD).
Several aggregation-prone proteins implicated in neuro-
degeneration were found to be sumoylated, and sumoylation-
deficient mutants showed an enhanced tendency to aggregate 
in cell-based assays. Together with the observation that SUMO 
proteins are among the most soluble proteins known and that 
SUMO as an artificial fusion tag helps to produce soluble re-
combinant proteins (Marblestone et al., 2006; Panavas et al., 
2009), it is plausible to speculate that sumoylation serves to 
regulate the solubility of aggregation-prone proteins.
Previous findings were based on cell-based assays only 
(Steffan et al., 2004; Mukherjee et al., 2009; Janer et al., 
2010); therefore, we aimed to approach this hypothesis di-
rectly by measuring the aggregation propensity of a purified 
sumoylated  and  unmodified  protein,  namely  -synuclein,   
a prototypic aggregation-prone protein that can be recombi-
nantly expressed at high levels and that plays a pivotal role in 
the pathogenesis of neurodegenerative diseases collectively 
called synucleinopathies.
-Synuclein is a natively unfolded neuronal protein that is 
enriched in presynaptic terminals (Iwai et al., 1995). Although 
-synuclein has been implicated in synaptic vesicle trafficking, 
its physiological functions remain largely enigmatic (Chandra 
et al., 2004, 2005). However, a central role in the pathology of 
PD, as well as Lewy body disease and multiple system atrophy, 
has been ascribed to -synuclein. Missense mutations and in-
creased gene dosage of -synuclein cause autosomal-dominant 
PD (Polymeropoulos et al., 1997; Krüger et al., 1998; Singleton 
et al., 2003; Zarranz et al., 2004). Another aspect of -synuclein 
is that it is a major constituent of the neuronal intracellular 
Lewy bodies that are a histological hallmark of PD and Lewy 
body disease.
Posttranslational  modifications  including  ubiquitination, 
phosphorylation, and nitrosylation of -synuclein have been re-
ported to play a role in -synuclein toxicity (Giasson et al., 
2000; Shimura et al., 2001; Fujiwara et al., 2002). More recently, 
-synuclein was found to be sumoylated upon overexpression in 
HEK293 cells. Based on mutagenesis/transfection experiments, 
lysine  102  serves  as  one  SUMO  acceptor  site;  however,  the 
K102R mutant protein was still efficiently modified. To date, a 
function for -synuclein sumoylation has not been published 
(Dorval and Fraser, 2006).
Here, we provide comprehensive and direct support for a 
role of sumoylation in protein aggregation in vitro and in vivo. 
Moreover, we show that sumoylation deficiency potentiates   
-synuclein neurotoxicity.
Results
As outlined in the previous section, the prototypic aggregation-
prone -synuclein seemed like an ideal candidate to study a 
possible impact of sumoylation on protein aggregation in vitro 
and in cells. However, sumoylation of -synuclein had so far 
only been observed upon overexpression in HEK293 cells   
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was then compared with that of unconjugated -synuclein puri-
fied under the same conditions (Fig. 2). The in vitro fibrillation 
process was monitored via Thioflavin T (ThioT) fluorescence. 
Interestingly, sumoylation of -synuclein completely abolished 
fibril formation even after 146 h of incubation (Fig. 2, A–C). In 
contrast, the presence of equimolar amounts of nonconjugated 
SUMO did not prevent fibril formation (Fig. 2, A, B, and D). 
Transmission EM (TEM) images confirmed the absence of fibril 
formation in the sumoylated -synuclein sample (Fig. 2 C) and 
the presence of amyloid fibrils formed by untagged recombinant 
-synuclein in a mixture with nonconjugated SUMO (Fig. 2 D).
In intact cells, only a small fraction of specific targets 
is usually sumoylated at a steady state. This can be a result of 
rapid cycles of conjugation and deconjugation or temporal or 
local control of sumoylation. Low levels of sumoylation are 
also observed for -synuclein, as shown in Fig. 1 B for trans-
fected cell cultures and in Fig. 1 C for brain from transgenic 
SUMO2 mice. Therefore, it was important to test whether   
-synuclein fibrillation would also be affected when <100%   
-synuclein was modified. Therefore, we mixed modified and 
unmodified -synuclein at ratios of 1:1 and 1:9 and again ana-
lyzed fibril formation. As shown in Fig. 2 (F and G), 50% of   
sumoylation was sufficient to completely block -synuclein 
fibrillation in vitro (Fig. 2, E–G). Most remarkable, however, 
was that -synuclein sumoylated to 10% was sufficient to cause 
an impressive 60-h delay in fibril formation (Fig. 2, I and J). After 
110 h of incubation, the fibrillation of -synuclein sumoylated 
to 10% reached a steady state. Of note, the addition of free 
SUMO in concentrations corresponding to 10, 50, or 100% un-
modified -synuclein had no effect on -synuclein fibrillation 
(Fig. 2, D, H, and L). Our results illustrate that sumoylated 
-synuclein fails to form fibrillar aggregates and that the cova-
lent conjugation of a single SUMO molecule even to a small 
proportion  of  -synuclein  molecules  substantially  delays  its   
fibril formation.
-Synuclein has multiple SUMO acceptor 
sites, the most significant of which are 
lysines 96 and 102
To test whether sumoylation also contributes to -synuclein sol-
ubility in cells, we needed to identify a sumoylation-deficient 
mutant. Although sumoylation of -synuclein on lysine 102 had 
been previously described (Dorval and Fraser, 2006), residual 
sumoylation suggests that additional lysines are also subjected 
to sumoylation. We thus mapped -synuclein SUMO acceptor 
sites by a combination of mutagenesis and mass spectrometry 
Figure 1.  -Synuclein sumoylation in vitro in cells and in mouse brain. 
(A) -Synuclein is SUMO2 modified in vitro. 500 ng -synuclein, 500 ng 
SUMO2, 150 ng Aos1/Uba2, 200 ng Ubc9, and 5–10 ng E3 ligase frag-
ments were incubated for 30 min at 30°C with and without ATP in a volume 
of 20 µl. Reactions were stopped with SDS sample buffer before analysis 
by SDS-PAGE and immunoblotting with mouse monoclonal anti–-synuclein 
antibody (Syn211; Invitrogen). (B) -Synuclein modification by SUMO2 in   
HEK293T cells. Plasmids encoding His6-SUMO2 (His6-S2) or/and -synuclein 
were transfected in HEK293T cells. SUMO substrates were purified by 
Ni
2+ affinity chromatography (Ni
2+-NTA) under denaturing conditions, 
and a sumoylated -synuclein band at 35 kD (stars in A and B) was 
detected with an -synuclein antibody (Syn211). 1% of total input (TP) and 
25% of elution fractions were loaded. (C, top) A schematic representation 
of the Thy1.2/His6-SUMO transgene. (bottom) -Synuclein sumoylation in 
mouse brain tissue. Total His6-SUMO2–conjugated proteins were isolated 
using Ni
2+-NTA affinity chromatography. TBLs and eluates were probed 
with anti–-synuclein antibody recognizing mouse -synuclein (clone 42). 
-Synuclein modified by a single SUMO2 molecule, indicated with a star, 
could be detected in the eluate obtained from His6-SUMO2 transgenics.
 JCB • VOLUME 194 • NUMBER 1 • 2011   52
-synuclein and identified modified lysine residues by MS analy-
sis (Hsiao et al., 2009). Of note, although we were able to re-
cord and annotate fragment spectra (tandem MS [MS/MS]), 
proving that K96 is indeed sumoylated (Fig. S2 A), we could not 
obtain a similar spectrum for a tryptic peptide derived from   
sumoylated -synuclein with SUMO conjugated to K102. In this 
case, we only recorded the exact molecular weight of this partic-
ular peptide (Fig. S2 B). Recording and annotation of a fragment 
spectrum of this particular peptide were hampered by the fact 
that the peptide (a) is very big (>6,900 D); (b) shows a charge state 
of +5 of the intact mass and, consequently upon fragmentation, 
(MS) approaches (Hsiao et al., 2009). -Synuclein contains one 
classical SUMO consensus acceptor site (K96: VKxD) and an-
other closely related motif (K102: GKxE). Hence, we generated 
single point mutations replacing K96 or K102 by an arginine. In 
addition, we constructed double and triple lysine-to-arginine mu-
tants mR1 (K6R, K10R, and K12R), mR2 (K21R and K23R), 
mR3 (K32R and K34R), mR4 (K43R and K45R), or mR5 (K58R 
and K60R) for the remaining nonconsensus lysines. However, 
none of these -synuclein mutations completely abolished or 
substantially  reduced  SUMO  conjugation  in  HEK293T  cells 
(Fig. 3 A). We then turned to the bacterially produced sumoylated 
Figure 2.  In vitro fibril formation of sumoylated -synuclein. (A) Coomassie staining of -synuclein sumoylated to 100% (lane 1) and -synuclein with   
an equimolar amount of free SUMO1 (lane 2). (B) Fibrillization kinetics of -synuclein sumoylated to 100% (70 µM; closed circles) and control condition   
(70 µM of nonmodified -synuclein + 70 µM of free SUMO1; open circles). (C) Nonamyloidogenic amorphous oligomers formed by -synuclein sumoylated 
to 100%. (D) Mature fibrils formed by control nonmodified -synuclein in the presence of 70 µM of free SUMO1. (E) Coomassie staining of -synuclein 
sumoylated to 50% (lane 1) and -synuclein with an equimolar amount of free SUMO1 (lane 2). (F) Fibrillization kinetics of -synuclein sumoylated to 50% 
(35 µM sumoylated -synuclein + 35 µM of nonmodified -synuclein; closed circles) and control condition (70 µM of nonmodified -synuclein + 35 µM of 
free SUMO1; open circles). (G) Nonamyloidogenic amorphous material formed by -synuclein sumoylated to 50%. (H) Mature fibrils formed by control 
nonmodified -synuclein in the presence of 35 µM of free SUMO1. (I) Coomassie staining of -synuclein sumoylated to 10% (lane 1) and -synuclein 
with an equimolar amount of free SUMO1 (lane 2). (J) Fibrillization kinetics of -synuclein sumoylated to 10% (7 µM sumoylated -synuclein + 63 µM of 
nonmodified -synuclein; closed circles) and control condition (70 µM of nonmodified -synuclein + 7 µM of free SUMO1; open circles). (K) Mature fibrils 
formed by -synuclein sumoylated to 10%. (L) Mature fibrils formed by control nonmodified -synuclein in the presence of 7 µM of free SUMO1. (C, D,   
G, H, K, and L) TEM of aggregation samples after 146 h of incubation in 50 mM Hepes and 100 mM NaCl, pH 7.4, at 37°C with constant stirring.   
ThT, Thioflavin T. Bars, 200 nm.53 Sumoylation of -synuclein • Krumova et al.
in the Orbitrap mass analyzed (Fig. S2 B) strongly suggests that 
this peptide is indeed the C terminus of -synuclein sumoylated 
at K102. No other tryptic fragment derived from -synuclein 
with or without conjugation with SUMO reveals a similar intact 
mass. We could thereby confirm K96 and K102 in the acidic   
C-terminal  region  as  SUMO  acceptor  sites  and,  in  addition, 
found eight other lysines in the N-terminal amphipathic region 
as well as the single lysine (K80) in the nonamyloid component 
(NAC) region (Figs. 3 B and S2 and supplemental data). In con-
clusion, at least 11 out of its 15 lysine residues can serve as 
SUMO acceptor sites. This is in line with our observation that, 
based on the migration behavior in polyacrylamide gels and   
despite  the  fact  that  -synuclein  is  predominantly  mono-
sumoylated, we sometimes observed faint, higher migrating addi-
tional bands that probably correspond to a minor proportion of 
polysumoylated -synuclein. However, two lysine residues in 
close proximity to each other (K96 and K102) account for >50% 
of the -synuclein SUMO conjugates, as simultaneous muta-
tion of both lysines (2KR double mutant) strongly impaired su-
moylation (Fig. 3 C). This double mutant served in the following 
cell-based analysis as a sumoylation-deficient mutant. However, 
because mutation of lysine residues may also influence ubiqui-
tination or acetylation, we wanted to have one additional mutant 
for functional assays. Therefore, we tested whether mutagenesis 
of the two acidic residues adjacent to the SUMO acceptor ly-
sines would also affect sumoylation (consensus SUMO acceptor 
sites require the acidic residue; Sapetschnig et al., 2002). Indeed, 
mutation of D98A and E104A (2A mutant) impairs sumoylation 
to a similar extent as the lysine-to-arginine mutations (Fig. 3 C). 
Of note, the ubiquitination status of -synuclein was not altered 
by mutating K96 and K102 (Fig. S3).
Impaired sumoylation of -synuclein 
increases inclusion formation and toxicity 
in HEK293T cells
Having identified two different -synuclein variants that are im-
paired in sumoylation, we wanted to compare their aggregation 
propensity and cytotoxicity with WT -synuclein. For this, we 
used a technique that allows visualization of -synuclein inclu-
sion formation in HEK293T cells (Opazo et al., 2008) by indi-
rect GFP labeling. Using this method, we transfected cells either 
with WT -synuclein or the mutants in which the main SUMO 
acceptor sites were abolished (2KR and 2A), all fused to a short 
(six amino acids) PDZ binding tag. WT -synuclein and mutant 
variants were coexpressed with a PDZ domain–GFP fusion 
protein. This approach allows GFP labeling of -synuclein by 
binding of the PDZ domain–GFP fusion protein to the small 
PDZ binding tag of -synuclein after both proteins have been 
expressed in cells. The technique avoids the use of an -synuclein–
GFP fusion protein, which bears a risk of altering -synuclein 
characteristics, including aggregation and toxicity, compared 
with the untagged protein (see Materials and methods; Opazo   
et al., 2008).
Cells were fixed 36 h after transfection, and the GFP fluores-
cence distribution pattern was quantified in a blinded fashion 
as  follows:  cells  with  homogenous  -synuclein  distribution 
(Fig. 4 A), cells with aggregates (Fig. 4 B), or cells with fragmented 
the charge states +4, +3, +2, and +1, which complicates the an-
notation and sequence assignment; and, (c) most importantly, 
that this particular peptide encompasses the extreme C terminus 
of -synuclein that lacks a C-terminal lysine or arginine and is 
thus not favorable for fragmentation under our conditions per se. 
In total, the size of the peptide together with its nontryptic nature 
prevented the generation of a meaningful fragment spectrum. 
Nonetheless, the exact mass of this particular peptide as revealed 
Figure 3.  K96 and K102 are the major sumoylation sites of -synuclein. 
(A) -Synuclein is sumoylated at multiple lysine residues. Sumoylation of   
-synuclein was analyzed in HEK293T cells by cotransfection of His6-SUMO2 
with WT myc-tagged -synuclein or one of the indicated lysine-to-arginine 
mutants (mR1: K6, 10, and 12R; mR2: K21 and 23R; mR3: K32 and 34R; 
mR4: K43 and 45R; and mR5: K58, 60R, K96R, and K102R), followed 
by Ni
2+-NTA chromatography. None of the mutations resulted in abolished 
-synuclein sumoylation. Total protein (TP) levels of WT -synuclein and the 
respective mutants are shown in the bottom panel. Samples were analyzed 
by immunoblotting with anti-myc antibody (9E10). (B) Summary of -synuclein 
sumoylation sites. MS analysis of sumoylated -synuclein (obtained upon 
sumoylation in bacteria; see Materials and methods) revealed 11 SUMO-
conjugated lysine residues (8 lysines in the N-terminal amphipathic region, 
1 lysine in the hydrophobic NAC region, and the 2 lysines in the C-terminal 
acidic region; Fig. S2 and supplemental data). Nonconsensus lysines are 
depicted in blue, and the consensus and consensus sequence–related sites 
are in red. (C) The sumoylation levels of myc-tagged WT, 2KR (K96R and 
K102R), and 2A (D98A and E104A) mutants were compared using Ni
2+-
NTA chromatography. Elution samples and total lysates (TP) in A and C 
were run on a 4–12% NuPAGE Bis-Tris gel and analyzed by immunoblot-
ting with myc antibody (clone 9E10). Sumoylated -synuclein runs as a 
doublet band on gradient SDS-PAGE.JCB • VOLUME 194 • NUMBER 1 • 2011   54
-synuclein  reduces  both  its  aggregation  and  toxicity  in 
HEK293T cells. To address specifically the role that SUMO 
plays in the regulation of -synuclein–induced toxicity in   
dopaminergic neurons in vivo, we compared the toxicity of WT 
-synuclein with -synuclein–2KR in a rat model of PD.   
To this end, we expressed -synuclein in dopaminergic sub-
stantia nigra (SN) neurons by recombinant adeno-associated   
viral vector serotype 2 (rAAV2)–mediated gene transfer. Over-
expression of -synuclein in dopaminergic neurons is a valid 
in vivo model for PD. It finds its equivalent in an enhanced ex-
pression as a result of -synuclein gene duplications or tripli-
cations, which cause familial forms of PD (Singleton et al., 
2003; Miller et al., 2004).
rAAV2 expressing EGFP, WT -synuclein, or -synuclein–
2KR under a neuron-specific promoter (Fig. 5 A) were stereo-
tactically injected into the left SN pars compacta (SNpc) of 
female Wistar rats. Brainstem sections were double stained for 
the dopaminergic cell marker vesicular monoamine transporter 2 
(VMAT2)  and  human  -synuclein  12  wk  after  injection. 
nuclei, the latter being indicative of cytotoxicity and apoptosis 
(Fig. 4 C). In agreement with our in vitro fibrillation assay, we 
observed that -synuclein that is largely sumoylation resistant 
(2KR mutant) leads to an increased proportion of cells with   
-synuclein  inclusions/aggregates  (Fig.  4  D).  Moreover,  the   
-synuclein–2KR mutant was substantially more toxic than 
WT -synuclein as measured by an increased apoptosis rate 
(Fig. 4 D). Importantly, the -synuclein 2A mutant (2A: D98A 
and E104A) that has no lysine substitutions behaved like the 
2KR variant, which further corroborates the hypothesis that the 
altered aggregation properties and enhanced neurotoxicity in-
deed represent sumoylation-dependent effects.
Mutations in the major SUMO acceptor 
sites of -synuclein exacerbate toxicity in 
dopaminergic neurons in vivo
Thus far, our results showed that covalent conjugation of a 
single SUMO molecule to -synuclein prevents it from fibril 
formation in vitro and provides evidence that sumoylation of 
Figure 4.  Sumoylation-impaired -synuclein mutants (2KR and 2A) induce increased toxicity and inclusion formation compared with WT -synuclein 
in HEK cells. (A–D) HEK293T cells were transfected with bicistronic plasmids expressing -synuclein variants (syn-WT; 2KR: K96 and 102R; and 2A: 
D98A and E104A) with a PDZ binding tag (HSTTRV) and PDZ domain–EGFP fusion protein (GFP). (A–C) Cells were classified in three groups based on 
GFP fluorescence distribution: homogenous (A), containing intracellular GFP-positive inclusions (B, arrowheads), and preapoptotic or having fragmented 
nuclei by DAPI staining (C). Images display exemplary cells to illustrate the different categories into which cells were grouped. Because individual cells 
displayed variations in expression levels, exposure times were adjusted differently to avoid overexposure. At the level of total cell lysates, expression 
levels of the different constructs were the same between the different experimental conditions. Bar, 20 µm. (D) Bar graphs represent percentages of all 
GFP-positive cells in the three categories summarized as mean ± SEM. Comparisons were made with KyPlot 5.0 using Student’s t test (*, P < 0.05;   
**, P < 0.01). n = 6. Note that cell counts were performed by direct observation at the microscope using identical optical parameters for all experi-
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revealed that injection of EGFP in the SNpc did not affect   
the survival of dopaminergic (VMAT2
+) neurons compared with 
the noninjected contralateral SNpc. However, injection of WT 
-synuclein resulted in a significant loss of VMAT2
+ SNpc neu-
rons (7,897 ± 1,007 surviving VMAT2
+ cells in WT -synuclein 
compared with 13,505 ± 201 in the EGFP control; P < 0.01; 
Proper neuronal transgene targeting is shown by fluorescence of 
EGFP and overlapping immunoreactivity for human -synuclein 
in VMAT2
+ SNpc cells (Fig. 5, A–C). Transgene expression levels 
were assessed in cultured primary rat cortical neurons (Fig. S4). 
Blind quantification of dopaminergic (VMAT2
+) SNpc neurons 
was performed by a stereological technique. Quantification 
Figure 5.  Reduced sumoylation exacerbates -synuclein neurotoxicity in vivo. (A) A schematic representation of vector genomes used in the in vivo rat 
model of PD. Recombinant adeno-associated viral vectors (AAV2) express either EGFP, WT -synuclein (syn-WT), or -synuclein K96R and K102R (syn-2KR) 
under the control of neuron-specific human synapsin 1 gene promoter (hSyn1). Vectors also encode inverted terminal repeats (TR) and small control elements 
woodchuck hepatitis virus posttranscriptional control element (WPRE) and bovine growth hormone (bGH)–derived polyadenylation site. (B) VMAT2-positive 
(VMAT2
+) neurons (red) in the left SN. (C) rAAV2-mediated GFP transduction of SNpc. (D) Overlay of VMAT2
+ and GFP-transduced neurons in the left SN. 
(E–G) Coimmunostaining of VMAT2
+ (red) and human -synuclein (green). Survival of VMAT2
+ neurons in SNpc of animals injected with rAAV2 vectors ex-
pressing EGFP (E), human WT -synuclein (F), or -synuclein–2KR (G). Panels B–G are each a composite of two separate fluorescent images (Axioplan2 with 
a 5× objective and AxioVision 4.7). (H and I) Respective unbiased stereological quantification of surviving VMAT2
+ (H) or NeuN
+ (I) cells in the transduced 
SNpc. The graphs display VMAT2
+ or NeuN
+ cell numbers in animals injected with rAAV2 expressing EGFP, WT -synuclein (syn-WT), and -synuclein–2KR 
(syn-2KR). N.I., contralateral noninjected side. n = 6–8 per experimental group. Results are mean ± SEM. **, P < 0.01, Student’s t test. Bars, 0.5 mm.JCB • VOLUME 194 • NUMBER 1 • 2011   56
found that 50% -synuclein sumoylation was sufficient to com-
pletely abolish -sheet/fibril formation in vitro and that as little 
as 10% sumoylation substantially delayed fibril formation.
Steric hindrance of -synuclein fibrillation 
by SUMO?
The exact molecular mechanism that leads to inhibition or   
delay in fibril formation upon sumoylation of -synuclein re-
mains unknown; however, a possible explanation is as follows:   
PD-associated amyloid fibrils are formed from protofibrils, which 
is characteristic for -sheet structures. Biochemical analysis and 
solid-state nuclear magnetic resonance experiments have re-
vealed a 7-kD fragment of -synuclein, comprising residues 
31–109, as a proteinase K–resistant core of the amyloid fibril 
(Miake et al., 2002; Heise et al., 2005; Vilar et al., 2008). More-
over, the C terminus of -synuclein is negatively charged, and 
there is evidence to suggest that its interaction with the NAC do-
main inhibits the aggregation of -synuclein (Bertoncini et al., 
2005). The two main SUMO acceptor sites K96/K102 that we 
identified are thus in very close proximity to the aggregation-
promoting amino acid stretch. Therefore, the steric barrier and 
shielding of the aggregation-promoting hydrophobic core may 
account for impaired fibril formation of sumoylated -synuclein. 
A similar inhibitory effect on in vitro -synuclein fibril forma-
tion has been observed by the addition of Hsp70 to the aggrega-
tion sample (Dedmon et al., 2005), which is probably a result of 
its binding to the hydrophobic core of -synuclein or to pre-
fibrillar intermediates. Nuclear magnetic resonance studies are 
planned to pursue this hypothesis at a structural level.
SUMO as a general solubility enhancer?
Our findings also raise the interesting possibility that dynamic 
conjugation and deconjugation of the highly soluble SUMO to 
several varying lysine residues throughout the protein may ful-
fill chaperone-like functions and keep the highly aggregation-
prone -synuclein fractions in solution. This would be in agreement 
with the presence of multiple alternative sumoylation sites in 
-synuclein, suggesting that the aggregation-inhibiting effect of 
SUMO modification may not be site specific. Similarly, a linear 
SUMO-huntingtin fusion protein displayed enhanced solubility 
(Steffan et al., 2004) independently from the SUMO acceptor 
site. Moreover, sumoylation has been suggested to modulate the 
solubility of aggregopathy-related proteins like superoxide 
dismutase-1 and proteins with CAG repeat expansion (Fei et al., 
2006; Mukherjee et al., 2009; Janer et al., 2010). Altogether, we 
therefore see the emerging general concept that sumoylation keeps 
-synuclein and other aggregation-prone proteins in solution.
Sumoylation: possible relevance  
for neurodegeneration
Fibril and aggregate formation are suspected to be important 
contributors to -synuclein neurotoxicity (Duda et al., 2000;   
Irvine et al., 2008). In our work, we identified a sumoylation-
deficient -synuclein mutant (2KR) with an enhanced propen-
sity to aggregate. It displayed substantially increased toxicity in 
a cell line as well as in the rAAV rat model of PD. Similarly, the 
solubility of the aggregation-prone ataxin 7 and androgen receptor 
Fig. 5, E and G), recapitulating the effect of increased gene 
dosage and overexpression of -synuclein in hereditary forms 
of PD (Singleton et al., 2003; Miller et al., 2004). Injection   
of rAAV2 encoding -synuclein that is largely impaired in 
sumoylation (synuclein-2KR) substantially exacerbated this 
neurodegenerative effect (4,577 ± 704 surviving dopaminer-
gic SNpc neurons or 42% less survival compared with WT   
-synuclein; P < 0.01; Fig. 5, F and G).
We then confirmed our results by an additional stereologi-
cal evaluation using neuronal nuclei (NeuN) as a neuronal marker 
independent of the dopaminergic phenotype. As expected, we 
observed  overall  higher  absolute  cell  numbers  in  all  groups 
compared with the dopamingergic cell marker VMAT2 (Fig. 5 H). 
Importantly, both the toxic effect of WT -synuclein and exac-
erbated toxicity of the sumoylation-deficient mutant could be 
recapitulated after evaluating the surviving NeuN-positive neu-
rons (Fig. 5 I). This result suggests that endogenous sumoylation   
of -synuclein at the main K96/K102 SUMO acceptor sites 
greatly reduces its neurotoxicity on dopaminergic SNpc neu-
rons in vivo.
Discussion
In this study, we provide direct in vitro and in vivo evidence 
for  SUMO’s  contribution  to  keeping  an  aggregation-prone 
protein soluble. We characterize sumoylation of -synuclein as 
a prototypic aggregating disease protein, show that sumoylation 
of -synuclein inhibits its fibrillation, and show that mutation 
of the main -synuclein SUMO acceptor sites leads to in-
creased toxicity.
SUMO modification maintains  
soluble -synuclein
Because  SUMO  is  one  of  the  most  soluble  proteins  (Bayer   
et al., 1998) whose attachment as an artificial fusion tag helps to 
produce otherwise difficult-to-purify proteins (Marblestone   
et al., 2006; Panavas et al., 2009), we examined whether the 
physiologically occurring modification of the aggregation-prone 
-synuclein by SUMO prevents its fibrillation. To that end, we 
generated large quantities of both sumoylated and nonmodified 
recombinant -synuclein. We did indeed observe that SUMO 
modification of -synuclein abolishes its fibril formation. This 
is the first time that SUMO’s impact on protein solubility and 
aggregation could be demonstrated directly in cell-free in vitro 
conditions. In agreement, we observed an increased aggregate 
formation in cells when the two major SUMO modification 
sites in -synuclein were abolished.
Both in cell-free assays and in cell culture, only a small 
fraction of -synuclein was sumoylated. However, this does not 
challenge the functional relevance of our finding. Low steady-
state levels of the highly dynamic SUMO modification can have 
a  major  impact  on  a  specific  protein’s  function  (Hardeland   
et al., 2002; Baba et al., 2005). Even if only a small percentage 
of -synuclein is modified at a steady state, the entire pool can 
go through rapid rounds of sumoylation and desumoylation, 
and, thus, the modification can have a significant impact on the 
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recombinant enzymes E1 (150 ng), E2 (200 ng), and E3 ligase (5–10 ng). 
Reactions, excluding controls, were incubated with 1 mM ATP at 30°C for 
30 min, stopped by addition of SDS sample buffer, and analyzed by 
SDS-PAGE and immunoblotting.
Recombinant expression and purification of sumoylated -synuclein
For large-scale generation of sumoylated -synuclein, we made use of a 
coexpression system developed by Uchimura et al. (2004). For this, the tri-
cistronic plasmid pT-E1E2S1 (provided by H. Saitoh, Kumamoto University, 
Kumamoto, Japan) driving overexpression of E1 and E2 enzymes and 
SUMO1 was cotransformed with nontagged human WT -synuclein in 
pT7-7 vector in BL21 (DE3) cells. Recombinant protein expression was in-
duced at OD600 0.5–0.6 with 0.5 mM IPTG, and cells were grown over-
night at 30°C. Cells were harvested and resuspended in 10 mM Tris, pH 8.0, 
and 1 mM EDTA, pH 8.0, and lysed using an emulsion flex (EmulsiFlex-C3; 
Avestin). After 20 min of boiling at 95°C and 100,000-g centrifuga-
tion, the supernatant was subjected to streptomycin sulfate at 10 mg/ml to 
precipitate DNA. After centrifugation at 100,000 g, the supernatant was 
precipitated using ammonium sulfate (to 0.36 g/ml). After centrifugation, 
the pellet was resuspended in 25 mM Tris-HCl, pH 7.7, and loaded onto a 
MonoQ column (GE Healthcare). Fractions containing sumoylated -synuclein 
(-synuclein*SUMO) were pooled, desalted on a PD10 column, and run 
a second time on the MonoQ column. After concentration, the sample 
was further purified using gel filtration in 50 mM Hepes and 100 mM 
NaCl, pH 7.4 (Superdex S75; GE Healthcare). 10 liters of overnight cul-
ture was used for purification of 2 mg sumoylated -synuclein. The SUMO1 
isoform was used for the production of sumoylated -synuclein in E. coli 
because SUMO2 chain formation complicated purification and drastically 
decreased the yield of mono-SUMO–conjugated substrate.
Ni
2+–nitrilotriacetic acid (NTA) affinity chromatography
His-tagged, SUMO-conjugated -synuclein was purified from cell culture 
lysates or brain homogenate using Ni
2+-NTA affinity chromatography 
under denaturing conditions. Ni
2+-NTA affinity chromatography with cell cul-
ture lysates was performed as previously described (Jaffray and Hay, 
2006). In brief, cells were lysed in 6 M guanidinium-HCl, 0.1 M Na2HPO4/
NaH2PO4, and 0.01 M Tris-HCl, pH 8.0, plus 10 mM imidazole, and ly-
sates were incubated with Ni
2+-NTA resin. Unbound material was washed 
out, and His-tagged, SUMO-conjugated proteins were eluted in 250 µl of 
buffer A (8 M urea, 100 mM NaH2PO4/Na2HPO4, and 10 mM Tris-HCl, 
pH 8.0, supplemented with 20 mM N-ethylmaleimide, 1 µg/µl aprotinin, 
1 µg/µl leupeptin, and 1 µg/µl pepstatin) plus 250 mM imidazole. Pull-
down experiments from mouse brain homogenates were performed as fol-
lows: 12-wk-old mice were decerebrated, and the brains were isolated 
and frozen in liquid nitrogen. Brain material was homogenized by grind-
ing in liquid nitrogen and resuspended in 10 ml of buffer A. Lysates were 
sonicated and centrifuged for 1 h at 100,000 g and at 8°C for the removal 
of debris. Supernatant was recovered and incubated with 500 µl Ni
2+-
agarose equilibrated in buffer A on a rotary shaker for 3 h at 8°C. After 
extensive washing with buffer A supplemented with 10 mM imidazole, buffer 
A supplemented with 0.2% Triton X-100 and 20 mM imidazole, buffer A 
supplemented with 0.1% Triton X-100 and 10 mM imidazole, and buffer 
A, bound proteins were eluted with 500 µl of buffer A, pH 8.0, with 250 mM 
imidazole. Eluates and total brain lysate (TBL) aliquots were methanol-
chloroform precipitated, and protein pellets were air dried and resuspended 
in SDS sample buffer, separated on 4–12% NuPAGE Bis-Tris gradient gels 
(Invitrogen), transferred on a nitrocellulose membrane, and probed with 
anti–-synuclein antibody (clone 42, 610787; BD).
Electrospray ionization–MS/MS for identification of SUMO sites
SUMO1-conjugated -synuclein (purified as described in the Recombinant 
expression and purification . . . section) was excised from gel, reduced 
with 50 mM DTT, alkylated with 100 mM iodacedamide, and in-gel di-
gested with modified trypsin (Promega) overnight, all at 37°C. Tryptic pep-
tides were dissolved in 2 µl of 50% acetonitrile in 18 µl of 0.1% formic 
acid for further MS analysis. Mass spectrometric analysis was performed 
by using a linear trap quadrupole mass spectrometer (Orbitrap; Thermo 
Fisher Scientific) equipped with a nanoelectrospray ion source and cou-
pled to an HPLC system (model 1100; Agilent Technologies) fitted with a 
homemade C18 column. Tryptic peptides were first loaded at a flow rate 
of 10 µl/min onto a C18 trap column, which was packed 1.5 cm in length 
with C18 material (Reprosil-Pur 120 Å, 5 µm, C18-AQ; Dr. Maisch GmbH) 
in a 360-µm outer diameter, 150-mm inner diameter capillary. Retained 
peptides were eluted and separated on an analytical C18 capillary col-
umn, which was packed 15 cm in length with C18 material (Reprosil-Pur 
120 Å, 5 µm, C18-AQ; Dr. Maisch GmbH) in a 360-µm outer diameter, 
with triplet repeat expansion was enhanced upon sumoylation 
and resulted in less toxicity (Mukherjee et al., 2009; Janer et al., 
2010). Although these data implicate a beneficial effect of   
-synuclein sumoylation on neuronal cell survival, reduction of 
the SUMO levels improved neuropathology in another in vivo 
neurodegeneration  paradigm,  the  Drosophila  melanogaster 
model of Huntington’s disease (Steffan et al., 2004). However, 
in this case, enhanced toxicity, despite reduced aggregate for-
mation, was accompanied by a stronger capacity to repress   
transcription in an in vitro assay. Hence, sumoylation of neuro-
degeneration-inducing substrates can alter their deleterious   
effect in either way, intensifying or reducing it, which is in 
agreement with the generally highly target-specific cell biolo-
gical effects of SUMO modification.
Thus, it is tempting to speculate that modification with 
SUMO proteins may play a role in the pathophysiology of PD; 
in addition to possible—so far, unknown—genetic defects that 
may alter the equilibrium of reversible sumoylation, the SUMO 
pathway is known to respond dramatically to many different in-
sults and environmental stresses, including heat, oxidative stress, 
viral and bacterial infection, and ischemia (Bossis and Melchior, 
2006; Kindsmüller et al., 2007; Cimarosti and Henley, 2008; 
Cimarosti et al., 2008; Yang et al., 2008; Chang et al., 2009). 
Specifically, oxidative stress has been linked to PD. For exam-
ple, an increase in production of reactive oxygen species as a 
result of mitochondrial dysfunction has been observed in animal 
models and implicated in the pathogenesis of PD (Fukae et al., 
2007; Zhou et al., 2008).
In conclusion, we provide a comprehensive in vitro and 
in vivo analysis that reveals SUMO’s impact on protein aggre-
gation  properties  using  a  prototypic  disease-related  protein 
prone to forming pathological intracellular inclusion bodies. 
Impaired sumoylation of overexpressed -synuclein contrib-
utes to PD-related characteristics of -synuclein, neurotoxic-
ity, and fibril formation (Fig. 6). To determine whether genetic, 
environmental,  or  oxidative  stress–induced  changes  in  su-
moylation contribute to the disease development will require 
extensive future investigations.
Materials and methods
In vitro sumoylation
In vitro sumoylation assays were performed in a total volume of 20 µl in 
SUMO assay buffer (110 mM KOAc, 20 mM Hepes, pH 7.3, 2 mM 
Mg[OAc]2, 1 mM EGTA, 1 mM DTT, 0.2 mg/ml BSA, and 0.05% Tween 20) 
supplemented with protease inhibitors (Werner et al., 2009). The reactions 
contained 0.5 µg recombinant SUMO2, 0.5 µg recombinant -synuclein, and 
Figure 6.  Proposed model for the role of sumoylation in -synuclein–
  induced neurodegeneration. SUMO prevents aggregation-prone fractions 
of -synuclein (S) from fibril formation. Impaired sumoylation may en-
hance the formation of -synuclein toxic species, which results in aggra-
vated dopaminergic cell death.JCB • VOLUME 194 • NUMBER 1 • 2011   58
PDZ assay
WT -synuclein or 2KR (K96 and 102R) was tagged with a six–amino acid 
PDZ binding motif (HSTTRV from neuroligin 1) and coexpressed with the 
corresponding PDZ domain (PDZ1 domain of synaptic scaffolding molecule) 
fused to GFP. To ensure equal expression levels and eliminate differences in 
transfection efficiencies, WT -synuclein and mutant tagged with the PDZ 
binding motif were subcloned in a bicistronic plasmid together with PDZ   
domain–GFP fusion under the same promoter (cytomegalovirus). HEK293T 
cells were Lipofectamine transfected with WT -synuclein or 2KR and 2A 
mutants and fixed 36 h after transfection. Cell counts were obtained manu-
ally. The advantage of this approach is that a fluorescent protein is not di-
rectly fused to -synuclein, and, at the same time, inclusions formed by 
-synuclein can be fluorescently labeled via the PDZ binding motif (Opazo 
et al., 2008).
Viral vector production
rAAV2 were used as gene delivery vehicles of EGFP, WT -synuclein, and 
-synuclein–2KR (K96R and K102R). Transgene expression was controlled 
by the highly neuron-specific human synapsin 1 (hSyn1) promoter (Kügler   
et al., 2001). Viral vectors were propagated in 293T cells using the pDG2 
helper plasmid (Grimm et al., 1998). Viral particles were purified according 
to established protocols (Zolotukhin et al., 1999) by iodixanol step gradient 
centrifugation. Samples were purified and concentrated by heparin affinity 
chromatography on an ÄKTA fast protein LC system using 1-ml HiTrap Hepa-
rin QFF columns (GE Healthcare) and desalted overnight by dialysis against 
PBS. Vector genomes were titrated by quantitative PCR. The purity of prepa-
rations was confirmed by SDS gel electrophoresis and silver staining.
Animal procedures
All experimental animal procedures were performed according to experi-
mental licenses issued by the responsible animal welfare authority of Nieder-
sächsisches  Landesamt  für  Verbraucherschutz  und  Lebensmittelsicherheit 
and controlled by the local animal welfare committee of the University of 
Göttingen. Intracerebral stereotaxic injections into SN of 2.5-mo-old female 
Wistar rats, sacrifice, and perfusion were performed essentially as previ-
ously described (Shevtsova et al., 2006). In brief, vector injections into 
SNpc were performed using a Kopf stereotaxic device with a computer-
controlled microinjector pump (Word Precision Instruments). Coordinates were 
as follows: anterior–posterior distance, 0.53; mediolateral distance, 0.22; 
and dorsoventral distance, 0.78, relative to bregma. A fine-bore glass 
capillary (30-µm diameter) was used to deliver the viral suspension.
Immunohistochemistry
PFA-perfused rat brains were frozen at 80°C and cut on a cryostat (CM 
3050 S; Leica) to 30-µm coronary sections. The brain sections were shortly 
washed with PBS-T (0.1% Triton X-100 in PBS) and incubated in a blocking 
solution (10% FCS and 0.1% Triton X-100 in PBS) for 1 h at RT to avoid un-
specific binding of the antibodies. Incubation with primary antibody (anti– 
-synuclein, 1:1,000 [32-8100; Invitrogen]; anti-VMAT2, 1:3,000 [AB1767; 
Millipore]; and anti-NeuN, 1:300 [MAB377; Millipore]) was performed 
overnight at 4°C in PBS with 0.1% Triton X-100 and 2% normal goat serum. 
After washing with PBS, the secondary Cy2- and Cy3-coupled antibodies 
(1:250 in PBS with 0.1% Triton X-100 and 2% normal goat serum) were ap-
plied for 1 h at RT. The unbound secondary antibodies were washed out, 
and sections were mounted on microscope slides (SuperFrost Plus; Thermo 
Fisher Scientific), embedded in polyvinyl alcohol mounting medium with 
DABCO (Fluca), coated by coverslips, and kept at 4°C until microscopy.
Microscope image acquisition
Wide-field fluorescent images were obtained at RT using an Axioplan2   
microscope equipped with a 5× LD Achroplan (Carl Zeiss) or 63× NA 1.4 oil 
objective (Carl Zeiss). The camera used was an AxioCam (Carl Zeiss), and 
Axiovision 4.7 (Carl Zeiss) was used as acquisition software.
Quantification of VMAT/NeuN-positive neurons in the SNpc
The number of VMAT- or NeuN-positive neurons in the SNpc was assessed 
using stereological methodology (West, 1999). Every third section was 
immunostained, and VMAT- or NeuN-positive neurons in the SNpc were 
counted from the left AAV2-injected side from a minimum of six animals per 
group using the optical dissector technique (Dehmer et al., 2004). The   
stereological quantification was performed using the Imager M2 microscope 
(Carl Zeiss). The software used was Stereo Investigator 6.0 (MicroBright-
Field, Inc.). Counts were performed manually and blinded for treatment. 
Statistical evaluation was performed with KyPlot 5.0 software (KyensLab 
Inc.) using Student’s t test.
75-mm inner diameter capillary at a flow rate of 300 nL/min, with a gradi-
ent from 7.5 to 37.5% acetonitrile in 0.1% formic acid for 60 min. Typical 
mass spectrometric conditions were as follows: spray voltage of 1.8 kV; 
heated capillary temperature of 150°C; and normalized collision-induced 
dissociation collision energy of 37.5% for MS/MS in linear trap quadru-
pole. An activation of q = 0.25 and an activation time of 30 ms were used. 
The mass spectrometer was operated in the data-dependent mode to auto-
matically switch between MS and MS/MS acquisition. Full-scan survey MS 
spectra (from m/z = 350–2,000) were acquired in the Orbitrap with a 
resolution of R = 30,000 at m/z = 400 (after accumulation to a target 
value of 1,000,000 in the Orbitrap). The five most intense ions were se-
quentially isolated and fragmented in the linear ion trap using collision- 
induced dissociation at a target value of 100,000. For all measurements with 
the Orbitrap detector, a lock-mass ion from ambient air (m/z = 445.120025) 
was used for internal calibration.
Identification of sumoylated lysine residues was performed exactly 
as described in Hsiao et al. (2009). ChopNSpice software (Hsiao et al., 
2009) was used to generate a concatenated protein sequence in order to 
identify the actual SUMO sites with the MASCOT search engine. For this, 
the FASTA sequence of -synuclein was chopped into tryptic fragments al-
lowing zero to three missed cleavages. The tryptic peptide sequence of 
SUMO1 that is putatively attached to any lysine residue within -synuclein 
is attached to the N terminus of each tryptic peptide of -synuclein that 
contains a lysine residue and a missed cleavage site. To avoid the genera-
tion of nonnatural peptides, a virtual amino acid “J” is attached to the   
C terminus of each tryptic fragment derived from -synuclein and SUMO1. 
The thus modified tryptic fragments are concatenated to yield a large novel 
FASTA sequence that is submitted into database search. Upon a database 
search with the search engine MASCOT, cleavage with an artificial endo-
proteinase was allowed that specifically recognizes N- and C-terminal J 
and a user-defined number of missed cleavages. The search engine then 
compares the in silico–generated and –concatenated tryptic peptides de-
rived from -synuclein attached to a tryptic peptide derived from SUMO1 
with the experimentally obtained fragment spectra by liquid chromatogra-
phy (LC)–MS/MS (Hsiao et al., 2009). The following parameters were 
used in the ChopNSpice software: the spice species was Homo sapiens; 
the spice sequence was SUMO1; the spice site was KX; the spice mode 
was once per fragment; include unmodified fragments in output; the en-
zyme was trypsin; allow up to three protein miscleavages; allow up to one 
miscleavage in the spice sequence; the output formatting was FASTA (sin-
gle protein sequence); mark all cleaved sites J; and retain comments in 
FASTA format without line breaks in FASTA output. For sumoylated site 
identification with MASCOT, all MS/MS spectra were searched against a 
new FASTA file that was created by ChopNSpice with the following param-
eters: mass tolerance of 10 ppm in MS mode and 0.8 D in MS/MS mode; 
allow zero missed cleavages; consider methionine oxidation and cysteine 
carboxyamidomethylation as variable modifications; and enzyme cleaved 
at J at N and C termini for MASCOT (also see supplemental data on MS 
fragments concerning sequence coverage of -synuclein and fragment spectra 
from sumoylated -synuclein tryptic peptides).
In vitro fibrillation assay
Recombinant  human  WT–  and  SUMO–modified  -synuclein  solutions 
were dialysed against 50 mM Hepes buffer with 100 mM NaCl at   
pH 7.4. To remove any potential seed before aggregation, samples were 
centrifuged for 2 h at 100,000 g at 4°C. Protein concentration was ad-
justed to 70 µM. 0.01% of sterile, filtered NaN3 was included in the ag-
gregation mixtures, which were then incubated in glass vials at 37°C 
with constant stirring at 200 rpm. For ThioT fluorescence measurements, 
5-µl aliquots were withdrawn from -synuclein incubations and added to 
2 ml of 5 µM ThioT in 50 mM glycine-NaOH, pH 8.2. Fluorescence mea-
surements were performed on a spectrofluorometer (Cary Eclipse; Var-
ian) using 3.5-ml quartz cuvettes (Hellma Analytics) with a path length of 
1 cm. Fluorescence emission spectra were recorded from 465 to 600 nm 
using an excitation wavelength of 446 nm, an integration time of 0.1 s, 
and both excitation and emission bandwidths of 10 nm. Kinetic aggrega-
tion traces were generated from time traces of ThioT fluorescence inten-
sity at 482 nm and corrected for free ThioT fluorescence. Data were 
normalized to the controls.
TEM
For negative staining, a solution containing protein was applied to glow-
discharged, carbon-coated grids and stained with 1% uranyl acetate. Images 
were taken in an electron microscope (CM120; Philips) at a defocus of 2.3 µm 
using a slow-scan charge-coupled device camera (TemCam 224A; Tietz 
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